大博医疗(002901.SZ)公告称，股东大博国际计划自公告披露之日起15个交易日后的3个月内以集中竞价 或大宗交易方式减持公司股份不超过8,280,390股，占公司当前总股本比例为2.00%，占剔除回购专户股 份数量后公司总股本比例为2.04%。减持计划实施期间，公司有发生送红股、资本公积金转增股本、增 发新股、配股等股份变动或除权事项，上述拟减持股份数量将相应进行调整。 ...

融券方面，当日融券卖出0.21万股，净卖出0.21万股。 来源：金融界 最近三个交易日，21日-25日，大博医疗分别获融资买入0.25亿元、0.28亿元、0.28亿元。 8月25日，沪深两融数据显示，大博医疗获融资买入额0.28亿元，居两市第2258位，当日融资偿还额0.32 亿元，净卖出447.56万元。 ...

Core Viewpoint - Dabo Medical's stock price increased to 58.69 yuan as of August 25, 2025, reflecting a rise of 0.28 yuan or 0.48% from the previous trading day, indicating positive market sentiment towards the company [1] Company Overview - Dabo Medical specializes in the research, development, production, and sales of orthopedic medical devices, with products covering trauma, spine, joints, and sports medicine [1] - The company is part of the medical device sector and the Fujian region, and it has been included in the 2025 mid-term report pre-increase concept [1] Market Performance - On August 25, 2025, the trading volume was 319 million yuan, with a turnover rate of 1.89% [1] - Dabo Medical was recently included in FTSE Russell and S&P related indices, leading to an increase in market performance expectations [1] Capital Flow - On August 25, 2025, there was a net outflow of 1.4897 million yuan in main funds, with a cumulative net outflow of 101 million yuan over the past five days [1]

Core Viewpoint - The article highlights that after the implementation of centralized procurement in the orthopedic high-value consumables sector, the industry has entered a new normal characterized by "price reduction and volume increase," posing significant challenges for manufacturers in terms of maintaining profits and cash flow. However, the company Dabo Medical has reported impressive results in its 2025 semi-annual report, showcasing a combination of rapid revenue growth, high profit elasticity, and significant cash flow improvement [2][10]. Financial Performance - Dabo Medical's revenue for the first half of the year reached 1.21 billion yuan, a year-on-year increase of 25.55%, while the net profit attributable to shareholders was 244 million yuan, soaring by 76.69% [6][11]. - The net profit growth rate significantly outpaced revenue growth, primarily due to a maintained net profit margin of around 20%, which is relatively high among domestic orthopedic companies [4][6]. - The overall gross profit margin stood at 71.01%, showing slight fluctuations compared to the same period last year [6][11]. Cost and Investment - The company effectively controlled expenses, with a slight decrease in the sales expense ratio, while R&D investment continued to rise, indicating improved overall efficiency [7][8]. - The gross profit margins for key segments are as follows: Trauma at 77.66%, Minimally Invasive Surgery at 77.55%, and Spine at 73.69%, while the Joint segment had a lower margin of 37.05% [7][26]. Cash Flow - The net cash flow from operating activities was 263 million yuan, reflecting a year-on-year increase of 96.30%, indicating that the company not only generated profits but also saw substantial cash inflow [9][11]. Business Progress - In the first half of 2025, Dabo Medical's revenue structure remained centered on Trauma, accounting for nearly 40% of total revenue, while the Joint, Neurosurgery, and other segments showed high growth rates, indicating a shift in the revenue structure [12][16]. - The overseas revenue accounted for over 10% of total revenue, growing significantly faster than domestic revenue, suggesting that Dabo Medical is not only maintaining its domestic market share post-procurement but also finding new growth opportunities abroad [13][16]. R&D and Product Layout - Dabo Medical's R&D expenses amounted to 160 million yuan, with a growth rate of 13.2%, indicating a commitment to maintaining R&D investment despite pricing pressures from centralized procurement [19][20]. - The company's strategy is characterized as "steady and balanced," ensuring profitability while keeping the product line competitive [23]. Risks and Opportunities - The company faces risks from ongoing centralized procurement price pressures, which have affected core categories such as joints, spine, and trauma [24][25]. - Future growth potential lies in the expansion of the Joint segment in lower-tier markets and overseas markets, with the latter showing a revenue growth rate of 40-50% [27][28]. - The ability to convert R&D investments into new product revenues will be crucial for maintaining competitive advantages in the industry [29].

据证券之星公开数据整理，近期大博医疗（002901）发布2025年中报。截至本报告期末，公司营业总收 入12.1亿元，同比上升25.55%，归母净利润2.44亿元，同比上升76.69%。按单季度数据看，第二季度营 业总收入6.6亿元，同比上升22.96%，第二季度归母净利润1.41亿元，同比上升84.47%。本报告期大博 医疗盈利能力上升，毛利率同比增幅6.21%，净利率同比增幅36.92%。 本次财报公布的各项数据指标表现尚佳。其中，毛利率71.01%，同比增6.21%，净利率21.42%，同比增 36.92%，销售费用、管理费用、财务费用总计3.78亿元，三费占营收比31.23%，同比减13.55%，每股净 资产7.59元，同比增1.69%，每股经营性现金流0.63元，同比增96.3%，每股收益0.6元，同比增79.9% | 项目 | 2024年中报 | 2025年中报 | 同比增幅 | | --- | --- | --- | --- | | 营业总收入(元) | 9.64Z | 12.1亿 | 25.55% | | 归母净利润(元) | 1.38 Z | 2.44亿 | 76.69% | | 扣非净利润 ...

证券之星消息，截至2025年8月22日收盘，大博医疗(002901)报收于58.41元，下跌0.15%，换手率 1.71%，成交量4.93万手，成交额2.86亿元。 8月22日的资金流向数据方面，主力资金净流出4421.62万元，占总成交额15.44%，游资资金净流入 270.85万元，占总成交额0.95%，散户资金净流入4150.76万元，占总成交额14.49%。 近5日资金流向一览见下表： 该股主要指标及行业内排名如下： | 指标 | 大博医疗 | 医疗器械行业均值 | 行业排名 | | --- | --- | --- | --- | | 总市值 | 241.83亿元 | 122.43亿元 | 9 123 | | 净资产 | 32.33亿元 | 38.93亿元 | 45 123 | | 净利润 | 2.44亿元 | 1亿元 | 14 123 | | 市盈率(动) | 49.5 | 77.99 | 57 123 | | 市净率 | 7.69 | 4.01 | 113 123 | | 毛利率 | 71.01% | 51.31% | 17 123 | | 净利率 | 21.42% | 10.85% | 33 1 ...

8月22日主力资金净流出4421.62万元，占流通市值比为0.26%；近五日主力资金累计净流出1.49亿元， 占流通市值比为0.88%。 风险提示：股市有风险，投资需谨慎。 来源：金融界 截至2025年8月22日15时，大博医疗股价报58.41元，较前一交易日下跌0.15%。当日开盘价为58.75元， 最高触及58.78元，最低下探至57.51元，成交额2.86亿元，振幅2.17%。 大博医疗主营业务为医用高值耗材的研发、生产与销售，产品涵盖骨科创伤类、脊柱类、关节类植入耗 材等。公司所属板块包括医疗器械、福建板块等。 8月21日披露的2025年半年报显示，公司上半年实现营业收入12.1亿元，同比增长25.55%；归母净利润 2.44亿元，同比增长76.69%；扣非净利润2.23亿元，同比增长82.64%。经营活动现金流净额2.63亿元， 同比增长96.3%。境外业务收入同比增长50.84%，占营收比重提升至13.02%。 ...

Group 1 - The core viewpoint of the news is that Dabo Medical (002901.SZ) has reported its semi-annual results for 2025, highlighting significant institutional investment in the company [1] - As of August 21, 2025, a total of 14 institutional investors hold shares in Dabo Medical, with a combined holding of 192 million shares, representing 46.36% of the total share capital [1] - The top ten institutional investors account for 46.23% of the total shares, with a decrease of 1.08 percentage points compared to the previous quarter [1] Group 2 - In the public fund sector, one public fund, Southern CSI 1000 ETF, increased its holdings slightly, while six new public funds were disclosed, including Dachen Multi-Strategy Mixed (LOF) A and Dachen Quality Medical Stock A [2] - Three public funds were not disclosed in the current period compared to the previous quarter, including Huabao CSI Medical ETF and Fuyong Medical Health Mixed Fund A [2] - Regarding foreign investment, one foreign fund, Hong Kong Central Clearing Limited, increased its holdings by 0.46% compared to the previous period [2]

大博医疗（SZ 002901，收盘价：58.5元）8月21日晚间发布半年度业绩报告称，2025年上半年营业收入 约12.1亿元，同比增加25.55%；归属于上市公司股东的净利润约2.44亿元，同比增加76.69%；基本每股 收益0.6007元，同比增加79.9%。 （文章来源：每日经济新闻） ...

Financial Performance - The company reported a total revenue of 1.21 billion yuan for the first half of 2025 [1] - The net profit attributable to shareholders was 244 million yuan [1] - The net cash inflow from operating activities was 263 million yuan [1] Key Financial Ratios - The latest debt-to-asset ratio stands at 25.91% [3] - The gross profit margin is reported at 71.01% [3] - The return on equity (ROE) is 7.77% [3] - The diluted earnings per share (EPS) is 0.60 yuan [3] - The total asset turnover ratio is 0.28 times [3] - The inventory turnover ratio is also 0.28 times [3] Shareholder Information - The number of shareholders is approximately 19,400 [3] - The top ten shareholders hold a total of 360 million shares, accounting for 86.93% of the total share capital [3] - The largest shareholder is Guangxi Dabo Business Communication Venture Investment Co., Ltd., holding 23.4% [3]